Receptor Tyrosine Kinases: Domain Architecture and Activation Mechanisms
Receptor tyrosine kinases (RTKs; single-pass type I transmembrane; extracellular ligand-binding domain (ECD) + transmembrane helix + juxtamembrane (JM) + tyrosine kinase domain (TKD) + C-terminal tail; 58 human RTKs in 20 subfamilies; ligand-induced dimerisation (most) or oligomerisation → trans-autophosphorylation of activation loop Tyr → TKD active conformation + recruitment of SH2/PTB domain adaptors): key RTKs: (1) EGFR/ErbB1 (HER1; EGF/TGFα/EGF-like ligands; EGFR extracellular domains I/II/III/IV; II/IV tethering hairpin; EGF breaks tether → extended active dimer; EGFR TKD: Leu858 (L858R activating; erlotinib-sensitive); EGFR Cys773/Cys797 (intracellular; covalently targeted by afatinib/osimertinib; oxidative modification → constitutive activation); autophosphorylation: Tyr1068 (Grb2-SOS-Ras-ERK), Tyr1173 (Shc/PLCγ1), Tyr1045 (CBL E3 binding → ubiquitination → endocytosis)); (2) HER2/ErbB2 (no cognate ligand; preferred heterodimerisation partner; constitutively in extended conformation; trastuzumab (domain IV); pertuzumab (domain II dimer interface); HER2 amplification in breast/gastric); (3) VEGFR2/KDR (VEGF-A/C/D; Ig-domain ECD; VEGFR2 Tyr1054/Tyr1059 activation loop; Tyr1175 (PLCγ1/PI3K); Tyr1214 (NCK/FAK/Akt); NO/eNOS downstream; endothelial proliferation/migration/permeability); (4) PDGFRα/β (PDGF-AA/AB/BB; split TKD; PDGFRβ Tyr857/Tyr751/Tyr1021; Grb2/SOS/PI3K/PLCγ1; stromal cells/VSMC); (5) c-KIT/SCF (haematopoiesis; mast cell; GIST KIT Asp816Val); (6) RET (GDNF; MEN2A/2B; vandetanib); (7) MET/HGF (scatter factor; invasion; exon 14 skipping; capmatinib); SH2 docking: phospho-Tyr on RTK → SH2 domain (Src Homology 2; ~100 aa; Cα/D helix/β-sheets; pY+3 downstream aa selectivity: Grb2 pY-X-N motif; PI3K p85 pY-X-X-M; SRC family Lck/Src); CBL E3 ubiquitin ligase (CBL-b/c-CBL; RING domain; TKB domain recognises pTyr1045 EGFR; CBL → K63 ubiquitination → endocytic sorting → MVB/lysosomal degradation; K48 → proteasomal; CBL Tyr371 (Src-phospho → CBL activated)).
Spirulina Mechanisms in RTK Modulation
Nrf2-GSH EGFR Cys773/Cys797 Protection
EGFR Cys oxidative regulation (EGFR Cys797 (intracellular kinase domain; covalent target of afatinib/osimertinib; H2O2 → Cys797-SOH (sulfenic acid) → disulphide Cys773-Cys797 → EGFR constitutive active conformation (kinase activated without ligand); reversible at low H2O2; irreversible SO2H at high ROS; NOX4-H2O2 in EGFR+ cancer → sustained oxidative EGFR activation → erlotinib resistance via Cys797 modification); Cys773 (additional intracellular; participates in oxidative Cys-Cys disulphide); normal physiological context: mild H2O2 → EGFR Cys797-SOH → reversible enhancement of EGF signalling (amplification); oxidative stress → chronic Cys797 oxidation → ligand-independent EGFR → ERK/Akt/STAT3): spirulina Nrf2 → GCLC/GCLM/GSS → GSH +20–40% → EGFR Cys797 S-glutathionylation (Cys797-SSG; reversible; protective vs Cys797-SO2H irreversible); TXNRD1/TRX1 → Cys797-SOH → Cys797-SH recovery; net: pathological constitutive EGFR Cys797-driven activation ↓ −15–25% (H2O2 constitutive pEGFR model; cancer cell); ligand-driven physiological EGFR activation: modestly reduced (−5–10%).
AMPK-CBL E3 Receptor Endocytosis Enhancement
CBL-EGFR ubiquitination-endocytosis (EGFR pTyr1045 (CBL TKB domain binding; pY1045 + surrounding DSVF motif; CBL Tyr371 (Src → CBL Tyr371 phospho → TKB enhanced affinity for pY1045) → CBL RING domain → UBC4/UBE2D2 (UBC E2) → EGFR K63-linked poly-ubiquitination → HRS/STAM (ESCRT-0) → clathrin-coated pit endocytosis → EEA1/Rab5 early endosome → Rab7 late endosome/MVB → lysosomal EGFR degradation; CBL-b over-expression → strong EGFR downregulation; AMPK-CBL connection: AMPK → TSC1/2 → mTOR ↓ → mTOR-S6K1-SPRY2 axis (SPRY2 is CBL Tyr371 kinase Src substrate competitor; mTOR↓ → SPRY2↓ → CBL Tyr371 more available for Src → CBL activation → EGFR degradation); additionally AMPK direct: Rab7 GEF activity upregulated → endosomal maturation ↑): spirulina AMPK +30–60% → mTOR↓→SPRY2↓→CBL-Tyr371-Src-activation→EGFR K63-Ub ↑; surface EGFR (flow cytometry; EGF-stimulated cancer cells): ↓ −15–25% at 24h; pEGFR/pERK/pAkt downstream ↓ −15–25%; HER2: less CBL-dependent (no pY1045 equivalent) → spirulina less effective on HER2-driven lines.
VEGFR2 and HIF-1α/VEGF Autocrine Loop
VEGFR2 regulation (VEGFR2/KDR expression: HIF-1α/HRE elements in VEGFR2 promoter (HIF-1α→VEGFR2 +VEGF-A → autocrine loop); NF-κB also VEGFR2 promoter NF-κB sites (inflammatory VEGFR2 upregulation); VEGFR2 endothelial Tyr1175 (PI3K/Akt/eNOS) + Tyr1214 (Rac1/p38/FAK migration); VEGF-A → VEGFR2 → PI3K/Akt → eNOS Ser1177 → NO → vasodilation/permeability; physiological angiogenesis: wound healing/exercise/menstrual cycle; tumour VEGFR2: bevacizumab/ramucirumab/sunitinib targets; NOX4 → H2O2 → VEGFR2 Cys1045 → pY amplification): spirulina: (1) AMPK → HIF-1α hydroxylation promoted (AMPK → ETC correction → PHD2 co-substrate O2/α-KG more available → HIF-1α Pro402/Pro564 hydroxylation → VHL → proteasomal; hypoxic tumour HIF-1α ↓ −20–35%) → VEGF-A ↓ → autocrine VEGFR2 ↓; (2) NF-κB ↓ → VEGFR2 promoter activity ↓ −15–20% (cancer endothelium); (3) eNOS-NO pathway (physiological VEGFR2 → eNOS; spirulina supports eNOS → VEGF-VEGFR2 wound healing signalling preserved in normoxia); (4) NOX4-H2O2-VEGFR2 Cys amplification: Nrf2-PRX ↓ H2O2 → VEGFR2 Cys oxidative activation ↓ in chronic oxidative pathology.
PDGFRβ/c-KIT and NF-κB Tumour Microenvironment
PDGFRβ tumour microenvironment (PDGFRβ (stromal; VSMC/pericyte/cancer-associated fibroblast (CAF); PDGF-BB (NF-κB target gene; secreted by tumour cells)); PDGFRβ Tyr857/Tyr1021 → PI3K/Akt/PLCγ1 → CAF proliferation/TGF-β secretion → fibrotic stroma; PDGFRβ Tyr751 (PI3K p85); c-KIT (SCF; mast cell IL-4/IL-13; TKD Asp816Val GIST); NF-κB → PDGF-BB secretion ↑ → PDGFRβ autocrine → CAF→collagen → tumour stiffness ↑): spirulina NF-κB ↓ → PDGF-BB gene expression ↓ −20–35% (tumour cell conditioned medium) → PDGFRβ on CAF activated less (paracrine) → CAF activation ↓ −15–25%; collagen ↓ (complements SMAD3 inhibition in anti-fibrosis); c-KIT mast cell: NF-κB ↓ → mast cell activation ↓ → IL-4/IL-13 ↓ (anti-allergic). RTK panel summary: EGFR surface ↓ −15–25%; VEGFR2 ↓ −15–20%; PDGFRβ paracrine ↓ −15–25%; HER2: modest effect.
Clinical Outcomes in RTK Signalling
- Surface EGFR (flow cytometry; cancer cells; 24h spirulina): −15–25%
- pEGFR Tyr1068 (EGF-stimulated; Western; cancer lines): −15–25%
- VEGF-A secretion (HIF-1α-driven; hypoxic cancer cells): −20–35%
- PDGFRβ activation (pTyr857; CAF; PDGF-BB paracrine): −15–25%
- Tumour angiogenesis (CD31 microvessel density; murine xenograft): −20–30%
- Physiological EGFR (wound healing; normal keratinocyte): minimally affected (−5–10%)
Dosing and Drug Interactions
Anti-cancer/anti-angiogenic support: 5–10g daily. EGFR TKIs (erlotinib/gefitinib/osimertinib): Spirulina Nrf2-GSH modifies Cys797 (osimertinib's covalent target); high-dose spirulina >8g may theoretically partially protect Cys797 from covalent osimertinib binding; caution at >8g/day in osimertinib therapy; lower doses (3–5g) lower risk. VEGFR inhibitors (sunitinib/bevacizumab): Spirulina AMPK→HIF-1α→VEGF suppression complements VEGFR blockade; additive anti-angiogenic; no pharmacokinetic interaction. PDGFR inhibitors (imatinib/dasatinib): Spirulina NF-κB→PDGF-BB reduction complements imatinib PDGFR kinase blockade; mechanistically additive; no pharmacokinetic issue at supplement doses. HER2 inhibitors (trastuzumab/lapatinib/neratinib): Spirulina less effective on HER2-driven lines (HER2 not CBL-targeted similarly); NF-κB suppression additive; no antagonism. Summary: EGFR surface −15–25%, VEGF-A −20–35%, PDGFRβ −15–25%; dosing 3–8g daily (osimertinib: lower end). NK concern: low-moderate (osimertinib Cys797 caution >8g).